A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Eligibility Criteria
Inclusion Criteria: * 1\. Those who voluntarily participated in this trial and provided informed consent; * 2\. Gender unlimited，18\<Age≤75; * 3\. Estimated life expectancy of minimum of 12 weeks; * 4\. ECOG 0-2; * 5\. Diagnosed as multiple myeloma according to the IMWG criteria; * 6\. Subjects failed treatment with at least 3 prior lines of therapy (including chemotherapy based on proteasome inhibitors (PIs) ，immunomodulatory agents (IMiDs) and CD38 antibody）, or recived the above three treatment methods experienced disease progression or recurrence during the most recent treatment process or within 6 months after the end of treatment, Difficulty in treatment includes primary difficulty in treatment ( patient has not achieved minimal remission or disease progression during treatment) or secondary difficulty in treatment (patient develops disease progression within 60 days after completion of treatment); * 7\. Women have a negative urine pregnancy test before the start of medication ad